Clinical outcomes after withdrawal of anti-tumor necrosis factor α therapy in patients with juvenile idiopathic arthritis: A twelve-year experience

Arthritis and Rheumatism

Volumn 63, Issue 10, 2011, Pages 3163-3168

  Baszis, Kevin ^a   Garbutt, Jane ^a   Toib, Dana ^a   Mao, Jingnan ^a   King, Allison ^a   White, Andrew ^a   French, Anthony ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADOLESCENT; ADULT; ARTICLE; CHILD; DISEASE EXACERBATION; DRUG WITHDRAWAL; FEMALE; HERPES ZOSTER; HUMAN; INFANT; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; MONONUCLEOSIS; OSTEOMYELITIS; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENCE RISK; REMISSION; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT DURATION; URINARY TRACT INFECTION;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULIN G; INFANT; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; WITHHOLDING TREATMENT;

EID: 80053533975     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30502     Document Type: Article

References (12)

1. Ravelli A, Martini A,. Remission in juvenile idiopathic arthritis. Clin Exp Rheumatol 2006; 24: S105-10. (Pubitemid 44696877)
2. Winthrop KL,. Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2006; 2: 602-10. (Pubitemid 44650948)
3. Diak P, Siegel J, La Grenade L, Choi L, Lemery S, McMahon A,. Tumor necrosis factor α blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. Arthritis Rheum 2010; 62: 2517-24.
4. Lovell DJ, Reiff A, Ilowite NT, Wallace CA, Chon Y, Lin S, et al, for the Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008; 58: 1496-504. (Pubitemid 351705939)
5. Ruperto N, Lovell DJ, Cuttica R, Woo P, Meiorin S, Wouters C, et al, for the Paediatric Rheumatology International Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 2010; 69: 718-22.
6. Tanaka Y, Takeuchi T, Mimori T, Saito K, Nawata M, Kameda H, et al, for the RRR study investigators. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. Ann Rheum Dis 2010; 69: 1286-91.
7. Saleem B, Keen H, Goeb V, Parmar R, Nizam S, Hensor EM, et al. Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped? Ann Rheum Dis 2010; 69: 1636-42.
8. Prince FH, Twilt M, Simon SC, van Rossum MA, Armbrust W, Hoppenregis EP, et al. When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis. Ann Rheum Dis 2009; 68: 1228-9.
9. Remesal A, De Inocencio J, Merino R, Garcia-Consuegra J,. Discontinuation of etanercept after successful treatment in patients with juvenile idiopathic arthritis. J Rheumatol 2010; 37: 1970-1.
10. Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-2. (Pubitemid 38160763)
11. Wallace CA, Ruperto N, Giannini EH, for the Childhood Arthritis and Rheumatology Research Alliance (CARRA), the Pediatric Rheumatology International Trials Organization (PRINTO), and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004; 31: 2290-4. (Pubitemid 39453253)
12. Russo RA, Katsicas MM,. Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. J Rheumatol 2009; 36: 1078-82.